StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Organic / Comparable Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

Latest, FY2025
10.2%
Period ended Dec 31, 2025
Change on a year earlier
+3.3 pts
6.9% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Organic / Comparable Sales Growth (%) (%)Year on yearSource
FY2025Dec 31, 202510.2%+3.3 ptsSEC Filing (0001628280-26-002982) ↗
FY2024Dec 31, 20246.9%-0.6 ptsSEC Filing (0001628280-25-002092) ↗
FY2023Dec 31, 20237.5%+6.0 ptsSEC Filing (0001628280-24-002009) ↗
FY2022Dec 31, 20221.5%-11.2 ptsSEC Filing (0001628280-23-001516) ↗
FY2021Dec 31, 202112.7%+23.5 ptsSEC Filing (0001104659-22-007648) ↗
FY2020Dec 31, 2020-10.8%-10.8 ptsSEC Filing (0001104659-21-007942) ↗
FY2019Dec 31, 20190.0%+1.5 ptsSEC Filing (0001104659-20-005717) ↗
FY2018Dec 31, 2018-1.5%+6.5 ptsSEC Filing (0001104659-19-002848) ↗
FY2017Dec 31, 2017-8.0%–SEC Filing (0001104659-18-003691) ↗

Cite this data

StockData. (2026). Abbott Laboratories Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Organic / Comparable Sales Growth (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-rm-yoy-org

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.